Literature DB >> 15252845

Amount of DNA in plasma and cancer risk: a prospective study.

Emmanuelle Gormally1, Pierre Hainaut, Elodie Caboux, Luisa Airoldi, Herman Autrup, Christian Malaveille, Alison Dunning, Seymour Garte, Giuseppe Matullo, Kim Overvad, Anne Tjonneland, Francoise Clavel-Chapelon, Paolo Boffetta, Heiner Boeing, Antonia Trichopoulou, Domenico Palli, Vittorio Krogh, Rosario Tumino, Salvatore Panico, H Bas Bueno-de-Mesquita, Petra H Peeters, Eiliv Lund, Carlos A Gonzalez, Carmen Martinez, Miren Dorronsoro, Aurelio Barricarte, M Jose Tormo, J Ramón Quiros, Goran Berglund, Goran Hallmans, Nicholas E Day, Timothy J Key, Fabrizio Veglia, Marco Peluso, Teresa Norat, Rodolfo Saracci, Rudolf Kaaks, Elio Riboli, Paolo Vineis.   

Abstract

Levels of plasma DNA concentrations in cancer patients have been shown to be higher than the plasma DNA concentrations found in healthy subjects. The value of plasma DNA levels for development of neoplastic or pulmonary disease was evaluated in a large prospective study. Plasma samples (n = 1,184) were analyzed from 776 controls, 359 cases of cancer (lung, bladder, oral cavity, pharynx, larynx, leukemia) and 49 deaths from chronic obstructive pulmonary disease (COPD), including never smokers and ex-smokers, from 9 countries across Europe. The amount of plasma DNA was variable across the European Prospective Investigation into Cancer and Nutrition (EPIC) centers. High DNA concentrations in some centers might be due to the type of population recruited and/or the treatment of the samples. An elevated and statistically significant odds ratio (OR) was found for COPD deaths (OR = 2.53; 95% CI = 1.06-6.02), while nonsignificant increased ORs were present for oral cancers, cancers of the pharynx and larynx and leukemia. When the analyses were stratified by time since recruitment (below or above 36 months), the increased ORs were limited to the more recent period of recruitment, i.e., a time elapsed between blood drawing and disease onset lower than 36 months. This was particularly true for COPD deaths (OR = 12.7; 95% CI = 1.57-103) and leukemia (OR = 2.37; 95% CI = 1.20-4.67). Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252845     DOI: 10.1002/ijc.20327

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  30 in total

Review 1.  Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.

Authors:  Bert Gold; Milena Cankovic; Larissa V Furtado; Frederick Meier; Christopher D Gocke
Journal:  J Mol Diagn       Date:  2015-05       Impact factor: 5.568

2.  Clinical Applications of Liquid Biopsies in Gastrointestinal Oncology.

Authors:  Anastasia Katsiampoura; Scott Kopetz
Journal:  Gastrointest Cancer Res       Date:  2014-09

3.  Evaluation of Streck BCT and PAXgene Stabilised Blood Collection Tubes for Cell-Free Circulating DNA Studies in Plasma.

Authors:  Kristina Warton; Nicole L Yuwono; Mark J Cowley; Mark J McCabe; Alwin So; Caroline E Ford
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

Review 4.  The clinical role of 'liquid biopsy' in hepatocellular carcinoma.

Authors:  Jessica A Howell; Rohini Sharma
Journal:  Hepat Oncol       Date:  2015-11-30

Review 5.  Cell-free nucleic acids as biomarkers in cancer patients.

Authors:  Heidi Schwarzenbach; Dave S B Hoon; Klaus Pantel
Journal:  Nat Rev Cancer       Date:  2011-05-12       Impact factor: 60.716

Review 6.  Molecular Profiling of Liquid Biopsy Samples for Precision Medicine.

Authors:  Camila D M Campos; Joshua M Jackson; Małgorzata A Witek; Steven A Soper
Journal:  Cancer J       Date:  2018 Mar/Apr       Impact factor: 3.360

7.  Performance of whole-genome amplified DNA isolated from serum and plasma on high-density single nucleotide polymorphism arrays.

Authors:  Daniel T Croft; Rick M Jordan; Heather L Patney; Craig D Shriver; Marina N Vernalis; Trevor J Orchard; Darrell L Ellsworth
Journal:  J Mol Diagn       Date:  2008-04-10       Impact factor: 5.568

8.  Circulating Cell-Free DNA from Colorectal Cancer Patients May Reveal High KRAS or BRAF Mutation Load.

Authors:  Florent Mouliere; Safia El Messaoudi; Celine Gongora; Anne-Sophie Guedj; Bruno Robert; Maguy Del Rio; Franck Molina; Pierre-Jean Lamy; Evelyne Lopez-Crapez; Muriel Mathonnet; Marc Ychou; Denis Pezet; Alain R Thierry
Journal:  Transl Oncol       Date:  2013-06-01       Impact factor: 4.243

9.  Potential for Raman spectroscopy to provide cancer screening using a peripheral blood sample.

Authors:  Andrew T Harris; Anxhela Lungari; Christopher J Needham; Stephen L Smith; Michael A Lones; Sheila E Fisher; Xuebin B Yang; Nicola Cooper; Jennifer Kirkham; D Alastair Smith; Dominic P Martin-Hirsch; Alec S High
Journal:  Head Neck Oncol       Date:  2009-09-17

10.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.

Authors:  Alain R Thierry; Florent Mouliere; Celine Gongora; Jeremy Ollier; Bruno Robert; Marc Ychou; Maguy Del Rio; Franck Molina
Journal:  Nucleic Acids Res       Date:  2010-05-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.